Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens

Vaccine

Volumn 19, Issue 32, 2001, Pages 4720-4726

  Scheifele, David W ^a   Halperin, Scott A ^b   Ferguson, Alexander C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Children; Immunity; Pertussis vaccine; Vaccine safety

Indexed keywords

ALUMINUM POTASSIUM SULFATE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; POLIOMYELITIS VACCINE; SODIUM CHLORIDE;

ALLERGY; ANALYTIC METHOD; ARM MOVEMENT; ARTICLE; ATOPY; CELLULAR IMMUNITY; CONTROLLED STUDY; DELTOID MUSCLE; DIAGNOSTIC TEST; DIPHTHERIA; ERYTHEMA; FEMALE; FEVER; HUMAN; IMMUNITY; INFLAMMATION; INJECTION SITE; MALE; MEDICAL RESEARCH; NORMAL HUMAN; PATCH TEST; PERTUSSIS; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN MANIFESTATION; SKIN TEST; TETANUS;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; BLISTER; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; ECZEMA; EDEMA; ERYTHEMA; FEMALE; FEVER; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; INJECTIONS, INTRAMUSCULAR; MALE; PAIN; PATCH TESTS; RESPIRATORY HYPERSENSITIVITY; SKIN DISEASES; VACCINATION; VACCINES, COMBINED;

EID: 0035860578     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00230-4     Document Type: Article

References (23)

1. Comparison of 13 acellular pertussis vaccines: Adverse reactions
2. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine
3. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old
4. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
5. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four, six months of age
6. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants
7. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life
8. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines
9. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children
10. Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children
11. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age
12. Role of whole-cell pertussis vaccine in severe local reactions to the preschool (fifth) dose of diphtheria-pertussis-tetanus vaccine
13. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines
14. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines
15. Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization
16. Local adverse reactions following a booster dose of acellular pertussis-DT vaccine: Lack of effect of loratidine prophylaxis
17. Delayed hypersensitivity to tetanus toxoid in man: In vivo and vitro studies
18. Relationship between cutaneous delayed hypersensitivity and cell-mediated immunity in vitro responses assessed by diphtheria and tetanus toxoids
19. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens
20. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines
21. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series
22. Skin immunization made possible by cholera toxin
23. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants